ALX Oncology raises $105 million in Series C financing for CD47 trials
By Akshay Kedari  Date: 2020-02-14

ALX Oncology raises $105 million in Series C financing for CD47 trials

ALX Oncology, a clinical-stage biotechnology company, has secured $105 million in a Series C funding round, led by Vivo Capital. The new investors, who participated in the funding round include Janus Henderson, Logos Capital, Foresite Capital, BVF Partners, HBM Healthcare Investments, and Cormorant Asset Management. The Series C funding round also witnessed the participation of existing investors Lightstone Ventures and Existing investors venBio, who had participated in the previous two rounds.

The latest funds will be used to further phase 2 study of CD47 myeloid checkpoint inhibitor ALX148 along with other anti-cancer treatments. The Series C funding round comes after the revelation of data by ALX on patients suffering from relapsed or refractory non-Hodgkin lymphoma (NHL), who have been treated using ALX148 in combination with rituximab. Among the 21 evaluable subjects, the company observed a median progression-free survival of 7.3 months and an objective response rate of around 43%. The drug was noted to be well tolerated and relatively safe.

Corey Goodman, Co-Founder and Executive Chairman, ALX, reportedly stated that from the initial days, the company believed that it will be the best-in-class in the CD47 checkpoint pathway by utilizing a ‘dead’ Fc domain that does not bind to macrophages, thus lessening the cytopenias and other toxicities related to this class of agents. The company is elated to observe the clinical results supporting its hypothesis and offering the opportunity for higher dosing and increased efficacy, he further added.

The phase 1 study, that generated the lymphoma data is progressing with other arms of the trial testing the potential of CD47 in combination with Keytruda and Herceptin in patients suffering from a solid tumor. But, with ALX148 coming through its first trial in NHL, ALX intends to take the candidate deeper into the clinic. The series C financing proceeds will be used to bankroll the further development of ALX148. 
 

Source links:

https://www.fiercebiotech.com/biotech/alx-raises-105m-for-midphase-trials-cd47-cancer-drug

 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Kerbal Space Program unveils new ESA missions simulation update
Kerbal Space Program unveils new ESA missions simulation update
By Akshay Kedari

Kerbal Space Program, a space flight simulator video game, has launches its new Shared Horizons update across the European frontier. Reportedly, this new update would allow players to recreate ESA (European Space Agency) missions to Mercury and to a ...

Google acquires Canadian augmented reality wearables firm North
Google acquires Canadian augmented reality wearables firm North
By Akshay Kedari

In a recent turn of events, a Canada based augmented reality (AR) wearables company North, has reportedly been acquired by Google for an undisclosed valuation. Based on the reports from Globe and Mail, the deal accounted for USD 180 million. For tho...

Librestream raises $24M through CBGF-led Series-D funding round
Librestream raises $24M through CBGF-led Series-D funding round
By Akshay Kedari

Winnipeg based augmented worker enterprise solutions provider, Librestream, has reportedly raised an amount of $24 million through a Series-D funding round led by Canadian Business Growth Fund (CBGF). The company will use the procured funds to boost ...

John Lewis to soon unveil its biomethane gas filling station
John Lewis to soon unveil its biomethane gas filling station
By Akshay Kedari

UK-based retail giant, John Lewis Partnership has recently announced construction of its dedicated biomethane gas filling station in an effort to curb carbon emission. This move is deemed to be a part of the its vision to become carbon neutral across...

Samsung semiconductor plants receive ULs environment certification
Samsung semiconductor plants receive ULs environment certification
By Akshay Kedari

Since many years now, Samsung Electronics Co. Ltd., one of the largest semiconductor manufacturers in the world, has been taking proactive steps to reduce its carbon footprint. Recently, the electronics giant has received the Zero Waste to Landfill c...